Articles & Presentations
IMS works with a variety of media outlets and trade associations to share expertise on issues impacting the pharmaceutical industry. This section provides abstracts and PDFs of current published articles, as well as extracts from recent industry presentations.
Biosimilars: How Strong a Market?
Generic drug companies have long been interested in the business of biosimilars ― or lower-cost “generic” versions of brand-name biotech drugs. At the same time, biosimilars represent a challenge to biotech companies, much the way generics do to pharmaceutical manufacturers. With biotechs accounting for about 10 percent of the $640 billion world pharmaceutical market and increasing at a 17 percent annual pace, the possibilities for biosimilars are only growing.
Sep 4, 2007
As Drug Budgets Tighten, Orphan Drugs Are Coming in for Scrutiny
So-called orphan drugs ― defined as a product treating a patient population of fewer than 200,000, or one for which a company has no reasonable expectation of recovering its R&D costs through sales ― have enjoyed favorable market access in the U.S. and in the European Union. But that could be changing, as the number of such drugs increases and drug budgets come under pressure.
Aug 17, 2007
IMS Health Special Report: Medicare Part D: The First Year
The introduction of the Medicare Part D benefit on January 1, 2006, was a watershed event in U.S. healthcare. Not since the introduction of Medicare in 1965 had such a far-reaching social program been provided to a potential population of almost 30 million people. While 2006 was very much an inaugural year for the program, looking at the first year in retrospect provides useful early indicators on the impact of this program on Medicare beneficiaries, as well as other healthcare stakeholders.
Jul 31, 2007
Can They Hear Us Now? Communicating the Value of Healthcare
Health economics and outcomes research (HEOR) provides critical data on the value of healthcare, but the language and techniques used to communicate the results often fail to convey the intended message. Health economists need to get back to communication basics to make their important message understood — and remembered.
Jun 2, 2007
Product Management Today Report
In this Product Management Today report, Taryn Tirrell, product marketing manager, and John Iacoviello, senior consultant, discuss how anonymized patient-level intelligence can be used to more accurately quantify and characterize opportunity in the metabolic syndrome market.
Nov 1, 2006
All Roads Lead to China
While growth in the global pharmaceutical market remains anemic, rising just six to seven percent in 2006, emerging economies are galloping ahead to outpace growth in mature markets like the United States and major European nations. Pharmaceutical companies are finding bright spots outside of these traditional markets to compensate for increasingly flat global growth. Within the last five years, the emerging markets’ share of growth in the global pharmaceutical market has grown from 5 percent to 31 percent. The most stellar opportunity lies in China, which continues to emerge as a significant healthcare market. To look at growth in China is to see that all roads lead to this awakening giant that will dominate as the world’s largest economy by 2040. IMS Global Consutling’s Raymond Hill, Stephen Walter and Mandy Chui explore these dynamics.
Oct 1, 2006
Traveling Through Time to More Accurately Forecast Brand Performance
In this Product Management Today report, Heather von Allmen, senior principal, Performance Management and Wesley Stuchlak, senior principal, Portfolio and Product Development, IMS Management Consulting, discuss how using anonymized patient-level intelligence, a brand team uncovered a previously unrecognized link in the demand for two therapies.
Sep 1, 2006
New-to-Brand Prescriptions: A More Accurate Assessment of New Business Growth
In this Product Management Today report, Gavin Krumenacker, director of Portfolio Optimization, IMS Health, discusses how anonymized patient-level information can be used to measure the volume of prescriptions generated by patients who are new to any given brand, which can serve as a key indicator of brand performance and future potential in the market.
Aug 1, 2006
Evaluating Changes in Market Dynamics in the Cholesterol-Lowering Drug Marketplace With Anonymized Patient-Level Information
In this Product Management Today report, John Lacoviello, senior consultant, PharMetrics, a unit of IMS Health, discusses how anonymized patient-level information can be used to understand how market disruptions can lead to changes in prescribing behaviors and ultimately, a brand's ability to gain new business by optimizing its business strategies.
Jul 1, 2006
Global Opportunities for Expanding Treatment Rates: A Hypertension Patient-Flow Model
Anonymized patient-level information can be used to develop patient-flow models that identify marketing opportunities and drive global investment plans for more efficient resource allocations.
Jun 1, 2006
|
| 
more
